Interruptions to cancer treatment (unscheduled radiotherapy breaks of 5 or more days) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (unscheduled radiotherapy breaks… compared with placebo; GRADE not reported.
1 finding from 1 review
Xerostomia (grade >= 2, 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to lower xerostomia (grade >= 2, 0-3 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in salivary flow rate (stimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes overall survival compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival (locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
1 finding from 1 review
Oral mucositis (moderate to severe) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (moderate to severe) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.30 [0.14, 0.65]
3 studies · 263 participants
Low
RR 0.85 [0.65, 1.11]
6 studies · 852 participants
Low
RR 0.79 [0.69, 0.90]
3 studies · 471 participants
High
Oral mucositis (severe) · breast cancer patients undergoing chemotherapy
Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.
1 finding from 1 review
Dysphagia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in dysphagia compared with placebo; GRADE not reported.
1 finding from 1 review
RR 1.32 [0.55, 3.13]
3 studies
GRADE not reported
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in locoregional tumour control compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge led to higher nausea (adverse effect) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review